SEC Form 4 · accession 0001654954-17-008693
Acer Therapeutics Inc. · ACER
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert D Steiner
Officer — Chief Medical Officer
Period of report
Sep 19, 2017
Accepted (ET)
Sep 21, 2017 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001069308
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonqualified Stock Option (right to buy)F1,F2 | $2.55 | Sep 19, 2017 | J | 40,000 | A | — | Apr 5, 2026 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1Received in connection with the Issuer's business combination (the "Merger") with what was then known as "Acer Therapeutics Inc." ("Private Acer") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated June 30, 2017 among the Issuer, Opexa Merger Sub, Inc. and Private Acer, in exchange for an option to acquire 40,000 shares of common stock of Private Acer.
- F2Option vests in eight equal quarterly installments beginning on January 1, 2016.